Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated develops and commercializes muscle-directed cardiovascular medicines, led by MYQORZO® (aficamten), a cardiac myosin inhibitor approved in the U.S., Europe and China for adults with symptomatic obstructive hypertrophic cardiomyopathy. Company news regularly covers MYQORZO clinical data, launch activity, regulatory approvals and analyses from HCM studies including SEQUOIA-HCM, MAPLE-HCM, FOREST-HCM and ACACIA-HCM.
Recurring updates also address Cytokinetics’ pipeline in cardiac muscle dysfunction, including omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. Financial releases and corporate announcements include product revenue, operating updates, shareholder voting matters, common stock offerings and other capital-structure developments.
Cytokinetics (NASDAQ: CYTK) will announce topline results from ACACIA-HCM on May 5, 2026.
The company will host a conference call and simultaneous webcast on Tuesday, May 5 at 8:00 AM Eastern Time. An archived replay will be available on the investor website for six months.
Cytokinetics (Nasdaq: CYTK) will present nine abstracts at the European Society of Cardiology Heart Failure 2026 Congress in Barcelona, May 9–12, 2026. Eight presentations focus on MYQORZO (aficamten), including a late‑breaking oral MAPLE‑HCM presentation; one presentation covers omecamtiv mecarbil and several moderated and ePoster sessions report clinical and real‑world HCM findings.
Cytokinetics (Nasdaq: CYTK) will report first quarter 2026 results on May 5, 2026 at 4:00 PM ET, followed by a senior management conference call at 4:30 PM ET to discuss financial results and business updates.
The call will be webcast simultaneously and an archived replay will be available on the company's investor website for six months.
Cytokinetics (Nasdaq: CYTK) announced inducement equity awards granted April 15, 2026 to 33 new employees hired March–April 2026.
The company granted 49,358 stock options (10-year term, $65.37 exercise price) and 32,734 RSUs that vest over three years per the stated schedule. Awards follow Nasdaq Listing Rule 5635(c)(4).
Cytokinetics (Nasdaq: CYTK) announced that company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 1:30 PM ET.
According to Cytokinetics, the event will be webcast live and the replay will be archived on the company website for 90 days.
Cytokinetics (Nasdaq: CYTK) granted inducement equity awards on March 13, 2026 to five new employees hired in February–March 2026: 8,628 stock options and 5,719 RSUs. Options carry a $60.06 exercise price and 10-year term; RSUs vest over three years per schedule. Awards follow Nasdaq Listing Rule 5635(c)(4) and are subject to the company's 2004 Equity Incentive Plan and award agreements.
Cytokinetics (Nasdaq: CYTK) announced four ACC 2026 presentations on MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), including pooled and subgroup analyses, treatment interruption data, hypertension subgroup results, and ECG‑echocardiography correlations.
Notable facts: regulatory approvals in US, EU, and China; pooled n=371; washout analysis n=182; ECG odds ratios significant (p<0.001).
Cytokinetics (NASDAQ: CYTK) said members of its management team will participate in four investor events in Miami Beach in March 2026: Leerink Global Healthcare (fireside, Mar 9), Citizens Life Sciences (fireside, Mar 10), Jefferies Biotech on the Beach (one-on-ones, Mar 11), and Barclays Global Healthcare (fireside, Mar 11).
Live webcasts of the fireside chats will be available via the company's Investors & Media website, with replay archives retained for 90 days after each event.
Cytokinetics (Nasdaq: CYTK) reported Q4 and full-year 2025 results, announced multi-region approvals for MYQORZO (aficamten), and began U.S. commercial launch with first prescriptions dispensed. The company ended 2025 with ~$1.22 billion in cash, reported full‑year 2025 revenue of $88.0 million, and provided 2026 GAAP R&D+SG&A guidance of $830–870 million.
Key upcoming milestones include ACACIA‑HCM topline in Q2 2026, a Germany launch in Q2 2026, and a potential MAPLE‑HCM sNDA decision in Q4 2026.
Cytokinetics (Nasdaq: CYTK) announced European Commission approval of MYQORZO (aficamten) 5 mg, 10 mg, 15 mg and 20 mg tablets to treat symptomatic obstructive hypertrophic cardiomyopathy (NYHA class II-III) in adults. First European launch is planned in Germany in Q2 2026; label allows starting doses of 5 mg or 10 mg.
The EC decision follows a positive CHMP opinion and joins prior approvals by the FDA and China NMPA.